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Hypertension is one of the most serious dis-
eases of the XXI century concerning about 20ñ30%
of the world population of adults. A significant
increase in the number of sick people is a result of
the lifestyle (stress and improper feeding habits).
Development in the diagnostic techniques and better
consciousness of population together resulted in an
increase of disease detection at the beginning stages.
Early detection and proper pharmacotherapy of
hypertension could decrease the risk of stroke, left-
ventricular hypertrophy, cerebral hemorrhage, cere-
bral vessel disease or peripheral artery disease (1, 2).
Diuretics, particularly thiazides and thiazide-like,
loop diuretics and potassium sparing diuretics are
applied in the hypertension treatment. From treat-
ment perspective, complexes consisting of the selec-
tive and nonselective β-adrenergic receptor antago-
nists and α-adrenergic receptor antagonists,
vasodilators, calcium channel blockers, ACE
inhibitors (from angiotensin-converting enzyme)
and angiotensin receptor antagonists play significant
role. 
Combined treatment proved to be more suc-
cessful than monotherapy during pharmacotherapy
studies of hypertension. Successful drug combina-
tions made from different pharmacological group
consist of:
● diuretic agent + β blocker (hydrochloroth-
iazide and metoprolol);
● diuretic agent + ACE inhibitors or
angiotensin receptor antagonists (hydrochloroth-
iazide and enalapril, hydrochlorothiazide and valsar-
tan, hydrochlorothiazide and candesartan); 
● diuretic agent + calcium channel blocker
(hydrochlorothiazide and amlodipine);
● diuretic agent + diuretic agent with different
way of action (hydrochlorothiazide and triamterene,
hydrochlorothiazide and spironolactone, furosemide
and spironolactone, furosemide and triamterene). 
Usage of combined treatment by application of
complex agents results in better hypotensive effi-
ciency of applied drugs. This improved efficiency is
achieved by synergic properties of different com-
pounds. Hypotensive drugs were divided based on
their chemical structure (3) as follows:
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Diuretics
a) 4-Chloro-3-sulfamylbenzoic acid derivatives




















pyrazine-2-carboxamide   
Triamterene
6-Phenylpteridine-2,4,7-triamine 
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d) Drugs with different chemical structures
Spironolactone
7α-Acetylthio-3-oxo-17α-pregn-4-
ene-21,17-carbolactone   
β-Blockers
a) 1-Aryl-2-alkylamine-1-propanol derivatives
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Diversity of chemical structures present in a
group of hypotensive drugs encourage for searching
new methods useful in their quantitative analysis.
The most commonly described in the literature are
spectrophotometric methods using zero-order spec-
trum or derivative spectrum curve, as well as chro-
matographic (GC, HPLC, TLC, HPTLC, CE) and
electroanalytical methods.
Spectrophotometric method (5ñ8)
Derivative spectrophotometry originates from
the classic spectrophotometry. It was developed by
differentiation of formula, which is a mathematical
illustration of Lambert- Beer law, and assumption of
stability of falling radiation intensity Io in the whole
studied wavelength [eq. 1]:
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dnA dnε
ñññññ = ñññññbc = nDx,λ [1]
dλn dλn
where: n ñ derivative order, λ ñ wavelength, nDx,λ ñ
derivative value of absorption spectrum of substance
X. 
Value of corresponding derivative depends on
direct proportion of a concentration of studied solu-
tion and thickness of the layer [eq. 1]. 
In the studied radiation range of the phase,
spectrum derivative of components is equal to total
value of individual components [eq. 2]:
nD1+ÖK= nD1+ nD2 + Ö+ nDK [2]
Equation [2] shows that the derivative of n
order of a mixture composed of K components at a
given wavelenght, is equal to the sum of derivative
values of n order of K components. 
In derivative spectrophotometry, the specific
feature is the dependence of derivative value on
peak half-intensity width. Thus, the derivative val-
ues increase when peak half-intensity width decreas-
es [eq. 3]:
nDA > nDB gdy LA < LB [3]
where: L is a peak width in half of its height. 
Due to application of derivative spectropho-
tometry, the folloving operations are possible: 
● determination of trace components without their
previous release from matrix;
● simultaneous determination of a few components
of the mixture;
● elimination of background, sample opacity, spec-
tra of disturbing substance with small run complex-
ity, (with broad or flat bands);
● usage even very small bands causing inflexion on
absorption curve or changes of slope angle;
● determination of precise values λmax, and also
points of inflexion;
● determination of organic compounds based on
derivative of specified order.
Derivative spectrophotometry was used by G.
Ragno et al., to analyze amlodipine and product of
its photodegradation in pharmaceutical preparations
(9). The process of photodegradation was carried
out at various ranges of radiation. In the first case,
the sample was exposed to sunlight from 9.00 AM to
5.00 PM in summer months (JuneñJuly). In the sec-
ond case, the sample was exposed to UV radiation
(280ñ360 nm, 30 W from 30 cm distance). Spectrum
records of zero order, its transformation into third
derivative and the wavelengths determination allow
for quantitative analysis of amlodipine (D3 λ = 243
nm) and its degradation product (D3 λ = 229 nm and
λ = 243 nm). The results obtained and their statisti-
cal estimation demonstrate the possibility of spec-
trophometric method application for such analyses.
Spectrophotometric method was also used for the
analysis of complex formulations containing various
substances of hypotensive action in its composition.
Cilazapril and hydrochlorothiazide were determined
quantitatively by spectrophotometric zero-order
method (10), after earlier establishment of chemo-
metric algorithm that allows for quantitative inter-
pretation of absorption spectra. Similar procedure
was undertaken to determine amiloride in the pres-
ence of hydrochlorothiazide (11). The first-order
method was applied for determination of benazepril
and hydrochlorothiazide (12). Application of this
method allows for determination of these active sub-
stances in a range 14.80ñ33.80 µg∑mL-1 for ben-
azepril and 18.50ñ42.20 µg∑mL-1 for hydrochloroth-
iazide, in spite of significant interference of particu-
lar components on zero-order spectra.
Commercially available Cibadrex 10/12.5 and
Cibadrex 20/25 were subjected for analysis. In both
cases, accuracy in determination was in the range of
99.3ñ99.9%. 
Interferences from active substances were
eliminated by applying derivative spectrophotome-
try for determination of candesartan and
hydrochlorothiazide (13), ibersartan and hydro-
chlorothiazide in CoAprowel 150/12.5 (14),
hydrochlorothiazide and losartan in Losazid and
Neo Lotan Plus (15). Two other active substances
from the group of hypotensive drugs, perindopril
and indapamide, were determined in Preterax by
using derivative spectrophotometry and LC method,
as a reference one (16). The obtained results showed
that spectrophometric method can be applied as a
competitive method to chromatographic techniques.
Statistically estimated parameters in both methods
were similar. Method accuracy (Xmean ± SD) with
application of derivative spectrophotometry was
99.1 ± 1.5% for perindopril and 98.5 ± 1.9% for
indapamide. For the LC method, these values were
98.4 ± 0.74% and 99.1 ± 1.28%, respectively. 
Derivative spectrophotometry was also applied
for the analysis of metoprolol formulation.
Rathiopharm composition contains 100.0 mg/tablet
of metoprolol formulation and 12.5 mg/tablet of
hydrochlorothiazide (17). At chosen wavelengths λ
= 317 nm for hydrochlorothiazide and 281 nm for
metoprolol, there is a possibility of determination of
active formulation components under conditions of
differential spectrophotometry for metoprolol.
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Application of the third derivative of absorption
spectrum allows for complete elimination of the
impact of hydrochlorothiazide on quantitative deter-
mination of metoprolol at the chosen wavelength.
Hydrochlorothiazide content was determined by
using zero-order spectrum.
Conversion of zero-order spectra into curves of
the first derivatives allowed for determination of
amiloride and furosemide (18) at λ = 241.4 nm and λ
= 343.6 nm, in the range from 6.9 ◊10-8 to 1.6 ◊ 10-4 M
(amiloride) and from 6.9 ◊ 10-8 to 0.8 ◊ 10-4 M
(furosemide), and atenolol at λ = 276.0 nm and
nifedipine at λ = 340.0 nm (19). Derivative spec-
trophotometry (D1 and D2) was successfully used
for a mixture of furosemide and spironolactone
(Lasilacton formulation containing 20 mg of
furosemide and 50 mg of spironolactone in a pill)
(20). Results of the determination with their statisti-
cal estimation confirmed the possibility of using
derivative spectrophotometry for determination of
those substances in complex pharmaceutical formu-
lations.
Derivative spectrophotometry was used as a
quantitative method for determination of enalapril
and valsartan in the presence of hydrochloroth-
iazide (21), or hydrochlorothiazide in the presence
of triamterene (22), in complex pharmaceutical for-
mulations. Determinations were done by the first
derivative method in a range 200ñ400 nm, assum-
ing for analytical wavelengths values of λ225 for
enalapril and λ278 for hydrochlorothiazide in deter-
mination of active substances in Enap HL formula-
tion. The concentration range was between 4.1
mg∑mL-1 and 20.5 mg∑mL-1 for enalapril, and 5.2
mg∑mL-1 to 26.0 mg∑mL-1 for hydrochlorothiazide.
For determination of valsartan in the presence of
hydrochlorothiazide in the formulation of Co-
Diovan, the second derivative was used at estab-
lished wavelengths: λ261 for valsartan and λ284 for
hydrochlorothiazide, and the concentration range
was 6.45 mg∑mL-1 to 32.25 mg∑mL-1 for valsartan
and 0.96 mg∑mL-1 to 4.8 mg∑mL-1 for hydrochloroth-
iazide. 
Hydrochlorothiazide and triamterene were
determined in Diureticum Verla formulation, by the
first and also the second derivative. The ranges stud-
ied were between 1.25 mg∑mL-1 and 6.25 mg∑mL-1 for
hydrochlorothiazide and from 2.4 mg∑mL-1 to 12.0
mg∑mL-1 for triamterene. For quantitative determina-
tion, the following wavelengths were chosen λ255.7
and λ240.9 in the case of first derivative or λ278.2 and
λ283.2 in the case of second derivative. The results
reported by authors were very accurate and precise,
confirmed by presented statistical parameters.
Chromatographic methods
Chromatographic methods are widely used in
the analysis of hypotensive drugs. These methods
are characterized by very high precision and possi-
bility of determination even several active sub-
stances simultaneously in analytical procedure. On
the other hand, time-consuming sample preparation
is often required. Repeatable, especially in case of
simultaneous analysis of active substances in bio-
logical material, sample preparation must be fol-
lowed by extraction to stationary phase and then by
elution, so the time of analysis is extended. 
HPLC and GC were applied for determination
of compound with hypotensive action in pharma-
ceutical preparations (23ñ26). The HPLC method
was also used to determine the concentration of
hypotensive drugs in systemic fluids. Solid phase
extraction of active pharmaceutical ingredients pre-
ceded their separation (27ñ32). Application of a
proper extraction method enabled determination
even a dozen or so compounds with good accuracy
and precision. In addition, development of good
analytical methods allowed to apply HPLC assay for
determination of both pharmaceutical active ingredi-
ents and their metabolites (28, 33ñ35) as well as
degradation products occurring during stress studies
(36). Such studies enable to understand metabolic
pathways of studied compounds and their behavior
in the body. Moreover, these studies gave the possi-
bility to determine degradation products of studied
compounds in vitro.
A possibility of identification and separation of
enantiomers is an important topic closely connected
with drug metabolism, bioavailability, formulation
and storage, and the efficacy of any therapy. For
some drugs, pharmacological activity depends on
the presence of some forms of the same pharmaceu-
tical active ingredient, which differ in its spatial con-
figuration. 
Separation and identification of enantiomers
was possible using chiral selectors in mobile or sta-
tionary phase or after stereoselective derivatization,
as well as through modification of extraction meth-
ods, mobile phases and system of detection (37, 38).
In HPLC, the separation of enantiomers was carried
out by usage of chiral stationary phases or derivati-
zation agents, such as triethylborane with ethyl
acetate, pentafluoropropionic anhydride, and trifluo-
roacetic anhydride. 
In TLC, the separation of enantiomers were
done on carriers coated with chiral stationary phas-
es or on nonchiral phases coated by selector like cel-
lulose and its derivatives (39ñ41). Densitometry was
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used mostly as a detection technique in planar meth-
ods. Table 1 shows examples of chromatographic
analysis of samples present in complex agents. 
Electroanalytical methods (62)
The most commonly used analytical methods
for the determination of hypotensive compounds are
electroanalytical methods (63) such as:
● cyclic voltammetry (CV);
● linear sweep voltammetry (LSV);
● stripping voltammetry (SV);
ñ anodic stripping voltammetry (ASV);
ñ catodic stripping voltammetry (CSV);
● square wave polarography (SWP), voltam-
metry (SWV);
● differential pulse polarography (DPP),
voltammetry (DPV);
Cyclic voltammetry was used for the analysis
of ramipril (64), amlodipine (65), and hydrochloro-
thiazide (66). Stripping voltammetry was applied
for determination of nifedipine (67), verapamil
Table 2. Electroanalytical methods used in the analysis of hypotensive drugs. 
Compounds Analyzed Methods Working electrode Reference
material  
Amiloride, pharmaceuticals DPP DME (74)
Hydrochlorothiazide
Atenolol, 
Propranolol gastric juce DPP DME (79)
Furosemide, pharmaceuticals, DPV, SWV GCE (70)
Pretanide human urine
Indapamide human serum DPV CPE, GCE (83)
ASV CPE (84)
pharmaceuticals, DPP DME (85)
Doxazosin human urine CSV CPE (86)
DPP, SWP HMDE (71)
Ramipril pharmaceuticals, CV, DPP DME, Pt (64)
biological fluids
Amlodipine pharmaceuticals, CV, SWV GCE (65)
biological fluids DPV GCE (87)
Prazosin pharmaceuticals DPP CPE (80)
DPP DME (81)
Nifedipine, Nimodipine hman urine and serum SV CPE (88)
pharmaceuticals, SWV HMDE (72)
Nifedipine human serum SV HMDE (67)
and plasma
Quinalapril pharmaceuticals SWV HMDE (73)
Captopril pharmaceuticals SWV HMDE (74)
DPP, SWV CGMDE (75)
Cilazapril, Quinapril, pharmaceuticals SWV HMDE (89)
Ramipril
Bisoprolol pharmaceuticals DPV GCE (90)
Spironolactone human urine SWV HMDE (76)
Furosemide human urine DPV HMDE (91)
Hydrochlorothiazide pharmaceuticals, CV GCE (66)
human urine
Verapamil pharmaceuticals, DPV GCE (92)
human serum, urine SV HMDE (68)
Nitrendipine, Nisoldypine phrmaceuticals DPV GCE (82)
Valsartan pharmaceuticals SV HMDE (69)
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(68) and valsartan (69), whereas square wave
polarography, voltammetry were used for
furosemide (70), doxazosin (71), amlodipine (65),
nifedipine (72), quinalapril (73), captopril (74, 75),
spironolactone (76) and candesartan (77). The
hanging mercury drop electrode (HMDE) or con-
trolled growth mercury drop microelectrode
(CGMDE) were mostly used as working elec-
trodes. Differential pulse polarography/voltamme-
try with modified carbon electrode (GCE or CPE),
mercury electrode (DME or HMDE) were applied
for analysis of amiloride and hydrochlorothiazide
(78), atenolol and propranolol (79), furosemide and
pretanide (70), prazosin (80, 81), nitrendipine and
nisoldipine (82).
It should be emphasized that electrochemical
methods need suitably prepared analyte and selec-
tion of electrolyte as well as appropriate type of
electrode. HMDE, CGMDE, DME, CPE, GCE and
metallic electrodes made from noble metals, most
frequently from platinum (Pt), gold (Au) and silver
(Ag), are used as working electrodes in the
described techniques. All mentioned electroanalyti-
cal methods are characterized by high detectability,
limit of determination, high sensitivity, and a possi-
bility of usage of different basic electrolytes in order
to obtain clear and well-developed signals, and pos-
sibility of reduction of the influence of templateís
compounds on the result of assay. Selected exam-
ples of the analysis of drug components are present-
ed in Table 2. 
CONCLUSIONS
Diversity in the chemical structures of hypoten-
sive drugs enables application of different methods of
quantitative and qualitative analysis of individual
components in pharmaceutical formulations. In the
cited literature, separation applications such as chro-
matography methods and capillary electrophoresis
are used for the quantitative analysis of formulations
containing several active substances. Authors of the
cited publications employed different stationary and
mobile phases and diverse detection methods in order
to obtain the best resolution of analyzed substances. 
Separation methods, and in some cases deriva-
tive spectrophotometry, were used in the analysis of
the complex agents by using different solvents and
derivative curves D1, D2 or D3. 
Electrochemical methods, due to their charac-
ter, are mostly used for the analysis of single sub-
stances. Electrochemical analysis of the complex
agents was usually preceded by their preliminary
separation through extraction preceded and then the
obtained eluent was processed by proper analytical
method.
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